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ABSTRACT
Case presentation:  We present a case of a 55-year-old Caucasian male with manifestations 
of dermatomyositis complicated with rapidly progressive interstitial lung disease (RP-ILD). 
Diagnosis of anti-MDA5 positive dermatomyositis was made.
Discussion: Myositis specific antibodies (MSA) can be used for diagnosis and predicting prognosis 
in patients with polymyositis and dermatomyositis. Anti-MDA5 positive dermatomyositis should 
be considered in patients presenting with dermatomyositis and a disease course resembling 
antisynthetase syndrome in the absence of antisynthetase autoantibodies, especially if a 
remarkably high ferritin is noted. Anti-MDA5 autoantibodies have been associated with RP-ILD 
and adverse outcome. In patients with anti-MDA5 autoantibodies, early diagnosis and aggressive 
immunosuppressive treatment may improve prognosis.
Conclusion:  This case highlights the importance of determining MSA in patients with 
dermatomyositis and associated interstitial lung disease, as this has implications for diagnosis, 
prognosis and therapy.
1. Introduction
Dermatomyositis is an inflammatory autoimmune dis-
order characterized by cutaneous manifestations and 
weakness of the proximal musculature with variable 
involvement of other organs [1]. The clinical presenta-
tion and disease course is variable and myositis specific 
antibodies (MSA) appear to be associated with distinct 
clinical phenotypes [2]. Anti-MDA5 autoantibodies are 
found in 7–13% of dermatomyositis and are associated 
with an amyopathic or hypomyopathic presentation and 
rapidly progressive interstitial lung disease (RP-ILD) 
with poor prognosis, but ethnical and environmental 
differences in presentation and prognosis have been 
proposed [2–4].
2. Clinical presentation
A 55-year-old Caucasian male with a history of psoria-
sis was referred with progressive respiratory failure. The 
patient had a four-month history of systemic symptoms 
starting with progressive fatigue, arthralgia, and diffuse 
muscle weakness followed by bilateral arthritis of the 
metacarpal joints and arthralgia of the wrists, Gottron’s 
papules, mechanic’s hands and an ulceration on the left 
ear. Approximately, one month after initiation of symp-
toms, the patient developed a non-productive cough and 
progressive dyspnea on exertion. These symptoms were 
accompanied by fever (39 °C) and night sweats. The past 
four months he lost 12 kg of weight.
Initial pulmonary function testing showed a restrictive 
pattern with a reduced diffusion capacity. Arterial blood 
gas showed hypoxemia (PaO2 64 mm Hg; PaCO2 34 mm 
Hg; pH 7.51; satO2 94%; A-a gradient 43.2 mm Hg). On 
lung high-resolution computed tomography (HRCT), 
diffuse subpleural and peribronchial inhomogeneous 
pulmonary infiltrates were present, together with atelec-
tasis and honeycombing in both lower lobes (Figure 1). 
A bronchoscopy with broncho-alveolar lavage was per-
formed. Cultures were negative. There was no evidence 
for malignancy on cytological evaluation. An increased 
CD4/CD8 ratio was noted. Laboratory findings showed a 
high sedimentation rate (35 mm/h), normal white blood 
cell count (3.5 103/μl), slightly elevated C-reactive protein 
(CRP) (19 mg/l), high ferritin (1669 μg/l), normal creatine 
kinase (CK) (14 U/l) and negative autoimmune serology 
(rheumatoid factor (RF), anti-cyclic citrullinated pep-
tide (anti-CCP), antineutrophil cytoplasmic antibodies 
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(ANCA), antinuclear antibodies (ANA)). Treatment 
with methylprednisolone 32 mg resulted in resolution 
of clinical symptoms and was then progressively reduced 
over a three-week period, after which relapse occurred. 
Methylprednisolone 2 × 40 mg was restarted, with dose 
reduction to methylprednisolone 32 mg after one week. 
A maintenance dose of methylprednisolone 32 mg was 
given in combination with sulfamethoxazol/trimeth-
oprim (Pneumocystis jirovecii prophylaxis). A positron 
emission tomography/computed tomography (PET-CT) 
scan showed heterogenous 18F-fluorodeoxyglucose 
(FDG)-avid groundglass infiltrates in both lungs, reac-
tive mediastinal lymph nodes, and a mild polyarthritis 
of the knees and hips. There were no findings suggestive 
of malignancy. Progression of parenchymal disease was 
confirmed on HRCT (Figure 2).
The patient was transferred to our department 
because of persistent respiratory failure. At that time, the 
systemic symptoms (arthritis, fever) had resolved under 
maintenance treatment with methylprednisolone 32 mg. 
An acute respiratory deterioration occurred with desatu-
ration: transcutaneous saturation fell to 80% (under 5 l/
min oxygen). The patient was admitted to the intensive 
care unit and treatment with amoxicillin/clavulanic acid 
4 × 1 g and clarithromycin 2 × 500 mg was started empir-
ically to cover potential infection. Methylprednisolone 
32 mg was continued. Thoracoscopic lung biopsy was 
performed. Histopathological evaluation showed marked 
thickening of the interalveolar septa with multiple foci 
of fibroblastic proliferation and extensive lymphocytic 
interstitial infiltration. Prominent hyperplastic type II 
pneumocytes were focally present. These findings were 
compatible with diffuse alveolar damage in the organiz-
ing (proliferative) stage (Figure 3). Screening for respira-
tory viruses was positive for human Metapneumovirus. 
Culture of broncho-alveolar lavage showed no bacteria. 
Extended testing for autoimmunity, with in particular 
testing for MSA, was performed: auto-antibodies for 
antisynthetase were negative, MDA5-auto-antibodies 
were markedly positive. Initially, the respiratory status 
progressively improved. The patient had normal oxygen 
saturation values under 1–2 l/min oxygen, but dyspnea 
and desaturation on exertion were still present. A treat-
ment plan with high pulse dose corticoid (1 g for 3 days) 
and cyclophosphamide (10 mg/kg) was made. However, 
a sudden acute respiratory failure with desaturation (to 
30%) and need for intubation occurred before this ther-
apy could be administered. A new HRCT-scan showed 
the presence of diffuse confluent consolidations in both 
lungs (Figure 4). Both the possibility of progression of 
the ILD or an infectious cause for the acute deterioration 
were considered. However, as the patient had no puru-
lent sputa, no fever, no signs of inflammation on initial 
laboratory evaluation and as microbiological cultures 
were negative, progression of the ILD was thought to be 
most likely. A first dose of cyclophosphamide (10 mg/
kg) and methylprednisolone (1 g for 3 days) was admin-
istered, followed by a maintenance dose of methylpred-
nisolone 80  mg. In addition, piperacillin/tazobactam 
was started for empirical anti-infectious coverage. On 
day 6 following intubation, the patient developed fever 
and a rising CRP (day 6: 15 mg/l; day 7: 80 mg/l) with 
the appearance of a new consolidation in the right 
lower lobe on chest radiography. Culture of aspirate 
showed Escherichia coli. Diagnosis of ventilator-associ-
ated pneumonia was made. Treatment was started with 
meropenem and downgraded to cefuroxime guided by 
antibiogram results. Repeat HRCT performed on day 11 
after treatment with cyclophosphamide and high dose 
corticosteroid showed a reduction of the consolidations 
in both lungs with residual consolidations in both lower 
lobes. Treatment with cyclophosphamide (10  mg/kg) 
was repeated. Unfortunately, after stopping cefuroxime 
(day 14), the fever relapsed with rising CRP (141 mg/l). 
Meropenem was restarted, but the patient developed 
progressive respiratory failure with increasingly difficult 
mechanical ventilation and died of intractable hypox-
emia and respiratory acidosis.
Figure 1.  First HRct showing diffuse subpleural and 
peribronchial infiltrates and parenchymal consolidations.
Figure 2. Second HRct (47 days after the first HRct) showing 
progression of peribronchial and parenchymal disease.
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3. Discussion
3.1. Dermatomyositis
Dermatomyositis is an autoimmune inflammatory 
disorder characterized by pathognomonic cutaneous 
manifestations such as Gottron’s papules and heliotrope 
eruption which can be accompanied by muscle weak-
ness [1,3,5]. Interstitial lung disease may be an important 
complication, and is rapidly progressive in some cases. 
Also, a wide variety of extrapulmonary manifestations 
are possible including fever, Raynaud’s phenomenon, 
arthralgia and nonspecific cutaneous modifications. The 
clinical spectrum is heterogeneous and may depend on 
the presence of a specific type of MSA [1]. Several MSA 
have been described and appear to be associated with 
distinct clinical phenotypes. Detection of these MSA 
may thus be useful in establishing the diagnosis and 
estimating prognosis [1].
3.2. Anti-MDA5 antibodies
Anti-MDA5 autoantibodies (initially named anti-
CADM-140) were at first described by Sato et al. in eight 
patients with clinically amyopathic dermatomyositis 
[6]. The target of this antibody was found to be a RNA 
helicase encoded by the melanoma differentiation-as-
sociated gene 5 [3,7]. Anti-MDA5 autoantibodies have 
been described in several east-Asian cohorts and appear 
to be associated with RP-ILD, more severe cutaneous 
vasculopathy and clinically amyopathic dermatomyosi-
tis [8,9]. Nevertheless, the presentation of anti-MDA5 
positive dermatomyositis can be diverse, varying from 
a more benign to a very aggressive disease course with 
RP-ILD. In the Caucasian population, the clinical pres-
entation of anti-MDA5-associated ILD is less well estab-
lished [3,10]. Although two North American cohorts 
suggested a less aggressive course of ILD, RP-ILD has 
also been described in Caucasian cohorts and case 
reports [2,11]. In addition, anti-MDA5 autoantibodies 
have shown to be associated with clinically amyopathic 
dermatomyositis. However anti-MDA5 autoantibodies 
are also frequently found in myopathic patients, espe-
cially in the Caucasian population as shown by Hall et al. 
[2]. Our case patient had subjective proximal weakness 
at presentation, but muscle enzymes were normal on 
initial laboratory evaluation.
To date, there is still controversy on the differences 
between populations in frequency and presentation of 
anti-MDA5 positive dermatomyositis. It is possible that 
genetic differences in susceptibility contribute to these 
differences in frequency and presentation. However, 
publication bias can be another explanation as litera-
ture on anti-MDA5 positive dermatomyositis in the 
Caucasian population is less extensive [2,3,12–14].
3.3. Rapidly progressive interstitial lung disease 
(RP-ILD)
Anti-MDA5 autoantibodies are associated with ILD, 
which especially in Asian cohorts is rapidly progressive 
and has a high mortality rate despite aggressive immu-
nosuppressive therapy [1,7,15,16]. However, a North 
American cohort showed a more benign course of ILD. 
In this cohort, ILD was present in 8 of 11 patients with 
anti-MDA5 autoantibodies, but only 2 patients were 
progressive on immunosuppressive therapy [2]. On the 
contrary, a Mediterranean cohort showed a more aggres-
sive disease course with RP- ILD occurring in 8 out of 14 
patients, with a 1-year mortality rate of 62,5% (5/8) [12].
A restrictive lung function pattern is expected in ILD. 
The main role of BAL is to rule out infection [3]. HRCT 
patterns of dermatomyositis-related ILD may include 
linear opacities, ground-glass attenuations, reticulation, 
peribronchovascular thickening, and consolidations. 
Honeycombing, traction bronchiectasis, and subpleural 
Figure 3.  thoracoscopic lung biopy: area showing impressive 
thickening of interalveolar septa by a cellular fibroblastic 
proliferation. A mild to moderately dense lymphocytic 
infiltrate is also present. Hematoxylin and eosin stain, original 
magnification: ×100.
Figure 4. third HRct (19 days after the second HRct) showing 
diffuse confluent consolidations in both lungs.
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antibodies [2]. Interestingly, screening of ANA may be 
negative in patients with anti-MDA5 autoantibodies, as 
can also be the case in antisynthetase syndrome [3].
3.6. Prognostic factors
Serum ferritin is significantly higher in anti-MDA5 
positive dermatomyositis compared with other MSA 
[15]. Therefore, if high ferritin is found in patients with 
dermatomyositis, anti-MDA5 positive dermatomyositis 
should be considered. High ferritin has been proposed 
as a negative prognostic factor in anti-MDA5 positive 
dermatomyositis [1,15,16,20]. Other negative prognos-
tic factors proposed in literature are an alveolar–arterial 
oxygen gradient of ≥ 32 mmHg and high anti-MDA5 
titers [15,21]. Interestingly, anti-MDA5 auto-antibody 
titers may decrease during treatment and may even dis-
appear during remission. In our case, these three prog-
nostic unfavorable factors were present [15,21].
3.7. Treatment
To date, evidence on the treatment of ILD in dermat-
omyositis is scarce. In general, corticosteroids remain 
the mainstay of treatment. In chronic ILD this might be 
sufficient [3]. However, the response rate in RP-ILD is 
much lower and additional immunosuppressive therapy 
added to high pulse dose corticoids is required [3,7]. In 
most case reports and cohorts, a combination of cor-
ticoids with cyclophosphamide and/or cyclosporin is 
used, although treatment with azathioprine, IV immu-
noglobulins and rituximab has also been described 
[2,3,22]. Early aggressive treatment should be started 
in case of RP-ILD, as it may improve prognosis. Our 
case patient was initially treated with methylpredniso-
lone 32 mg until definite diagnosis of anti-MDA5 pos-
itive dermatomyositis was made. A rapid deterioration 
occurred and treatment with high pulse dose corticoid 
and cyclophosphamide was started. Unfortunately, the 
patient developed progressive respiratory failure and 
deceased.
4. Conclusion
We present a case of a patient with anti-MDA5 posi-
tive dermatomyositis complicated with RP-ILD. Testing 
for anti-MDA5 antibodies among other MSA should 
be considered in patients with dermatomyositis who 
develop ILD, as ILD in anti-MDA5 positive patients may 
be rapidly progressive and early treatment is warranted.
Informed consent
Written informed consent was obtained from the 
patient’s legal representative before publication of this 
case report and accompanying images.
bands have also been described [3]. The pattern found 
on HRCT may suggest a histopathologic pattern, such as 
organizing pneumonia, nonspecific interstitial pneumo-
nia (NSIP), mixed NSIP-organizing pneumonia and less 
frequent a usual interstitial pneumonia (UIP) pattern. 
However, the correlation with histopathologic findings is 
rather limited. Histopathologic changes in dermatomy-
ositis-related ILD include NSIP, UIP, organizing pneu-
monia and diffuse alveolar damage [3]. A surgical lung 
biopsy is not strictly indicated in dermatomyositis-as-
sociated ILD, but can be performed in aspecific cases 
with diagnostic uncertainty [3,17]. If a clear diagnosis 
can be made on clinical evaluation, MSA and imaging, 
a surgical lung biopsy might not alter therapeutic deci-
sions based on this less invasive evaluation [3,17–19]. 
However, in our case, a lung biopsy was performed to 
rule out potential treatable causes of RP-ILD before diag-
nosis of anti-MDA5 dermatomyositis was made. A histo-
logical pattern compatible with diffuse alveolar damage 
in the organizing phase was noted, consistent with the 
rapidly progressive disease course. Previous histopathol-
ogy reports of RP-ILD in anti-MDA5 positive patients 
also show diffuse alveolar damage in most cases, but 
other patterns such as NSIP have been described [17,18].
3.4. Cutaneous manifestations
Anti-MDA5 autoantibodies have been associated with 
a more severe cutaneous vasculopathy with skin ulcer-
ations and tender palmar papules, next to the hallmark 
skin changes of dermatomyositis (e.g. Gottron’s pap-
ules, heliotrope eruption photosensitivity, shawl or ‘V’ 
sign, mechanic’s hands…) [11]. These skin ulcerations 
are mainly described on the Gottron’s papules and dig-
ital pulps, but can occur in other sites such as the ears 
[3,11]. Our case patient presented with Gottron’s pap-
ules, roughening of the skin with rhagades on the tips 
and sides of the fingers (mechanic’s hands) and an ulcer 
on the left ear.
3.5. Extrapulmonary manifestations
Other extrapulmonary and extracutaneous manifes-
tations are frequent in anti-MDA5 positive patients. 
Arthritis, Raynaud’s phenomenon, and fever are fre-
quently noted [3]. In the cohort of Hall et al., patients 
frequently presented with inflammatory arthritis sim-
ilar to rheumatoid arthritis. Eight of 11 patients with 
anti-MDA5 autoantibodies presented with the clinical 
manifestations of the antisynthetase syndrome (e.g. ILD, 
myositis, polyarthritis, fever, weight loss, Raynaud’s phe-
nomenon and/or mechanics hands) in the absence of 
antisynthetase antibodies, suggesting that anti-MDA5 
autoantibodies should be tested in patients with der-
matomyositis and a clinical course resembling anti-
synthetase syndrome without typical antisynthetase 
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